Targeting Taurine Transporter (TauT) for Cancer Immunotherapy of p53 Mutation Mediated Cancers - Molecular Basis and...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Taurine transporter (TauT) is a p53 target gene and is overexpressed in various human cancers.
• TauT expression is upregulated by oncogenes c-Myc and c-Jun.
• Blocking TauT function is explored as a strategy to inhibit tumor development.

Purpose of the Study:

• To investigate the effects of blocking TauT on tumor cell proliferation, apoptosis, and survival in preclinical models.
• To evaluate the therapeutic potential of TauT targeting approaches, including RNA interference and immune targeting.
• To assess the efficacy of a TauT peptide vaccine in p53-mutant mice models of spontaneous tumorigenesis.

Main Methods:

• RNA interference (RNAi) was used to knockdown TauT expression in human breast cancer MCF-7 cells.
• An antibody against TauT was employed to block taurine uptake and assess its effects on tumor cells.
• TauT peptide vaccination was administered to p53-null and p53+/- mice to evaluate its impact on lifespan and tumor growth.

Main Results:

• RNAi-mediated TauT knockdown induced G2 cell cycle arrest, suppressed proliferation, and enhanced apoptosis in MCF-7 cells.
• Antibody-mediated TauT blockade led to G2 arrest and cell death in various tumor cells without affecting normal cells.
• TauT peptide vaccination significantly increased median lifespan in p53-null and p53+/- mice.
• Treatment with TauT peptide reduced tumor size by approximately 50% and prolonged survival in tumor-bearing p53-null mice.

Conclusions:

• Targeting the taurine transporter (TauT) effectively inhibits cancer cell growth and survival.
• A novel TauT peptide vaccine demonstrates significant therapeutic potential for p53 mutation-related cancers.
• TauT peptide vaccines may serve as a universal cancer vaccine for preventing and treating p53-mediated cancers.